V
Verenium
Industrial biotechnology company specializing in the development of high performance enzymes
About Verenium
Verenium specializes in providing innovative solutions for the pharmaceutical industry, focusing on enhancing drug manufacturing processes to be more efficient, robust, and cost-effective. The company serves pharmaceutical manufacturers by offering a wide range of chemical raw materials, including APIs (Active Pharmaceutical Ingredients) like ibuprofen and omega-3. Operating in the global pharmaceuticals market, Verenium leverages its deep understanding of various industries, technologies, and applications to meet the specific needs of its clients. The business model revolves around supplying high-quality raw materials and excipients essential for drug formulation, ensuring that pharmaceutical companies can produce effective and safe medications. Verenium generates revenue through the sale of these specialized raw materials and by providing tailored solutions that address the unique challenges faced by its clients in drug production. The company is committed to sustainability and responsible care, adapting to the evolving landscape of the pharmaceutical industry, especially in light of the COVID-19 pandemic.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1992
- Headquarters
- Cambridge, United States
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 28.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Enzymes, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Sep 2013 | $62M | $62M | BASF | — |
| SERIES AOther financing | Dec 2012 | $7.3M | $29M | Undisclosed | — |
Growth signals
Latest recorded traffic for Verenium is 210 monthly website visits. Verenium's team declined 56.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
BP Global
Other known investors2 additional known investors
BASF
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Verenium on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Verenium’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.